GCase Chaperones Stabilize Enzyme for Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for treating neuronopathic Gaucher disease and Parkinson's disease, with no FDA or EMA-approved treatments available, and existing enzyme replacement therapies for Gaucher disease are inefficient due to the instability of the GCase enzyme, requiring frequent intravenous infusions.
Innovation Solution
Development of novel non-inhibitory β-glucosidase (GCase) chaperones that stabilize the GCase protein, enhance its activity, and facilitate its localization to lysosomes, allowing for oral administration and improved therapeutic efficacy in treating Gaucher disease and potentially Parkinson's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional enzyme replacement therapy with GCase is used, then therapeutic efficacy is achieved in visceral type Gaucher disease, but the treatment requires frequent intravenous infusions due to enzyme instability
Solution Approach 1:
The patent introduces chaperone molecules as intermediaries that bind to GCase enzyme to form a stable complex. The chaperone acts as a mediator that protects the unstable GCase from degradation, extends its half-life in the bloodstream, and facilitates its proper folding and trafficking to lysosomes, thereby resolving the contradiction between achieving therapeutic efficacy and maintaining prolonged drug action without frequent infusions
Solution Approach 2:
The patent creates a composite therapeutic system consisting of the chaperone molecule-GCase enzyme complex. This composite structure combines the stabilizing properties of the chaperone with the catalytic function of GCase, resulting in a more stable and长效 therapeutic agent that maintains efficacy over extended periods compared to GCase alone
2Reliability
If GCase is administered to treat neuronopathic Gaucher disease, then substrate accumulation may be reduced, but the enzyme cannot effectively penetrate the blood-brain barrier with conventional delivery methods
Solution Approach 1:
The chaperone molecule serves as an intermediary that not only stabilizes GCase but also facilitates its transport across the blood-brain barrier. The chaperone-GCase complex exhibits improved pharmacokinetic properties including enhanced brain penetration capability, allowing the enzyme to reach neuronal tissue and reduce substrate accumulation in the central nervous system
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of GCase by combining it with chaperone molecules. This changes the enzyme's stability, half-life, and tissue distribution characteristics, enabling effective delivery to the brain and other previously inaccessible tissues where conventional GCase administration failed
3Reliability
If frequent intravenous infusions are administered to maintain GCase therapeutic levels, then enzyme activity is maintained, but patient burden and treatment complexity increase
Solution Approach 1:
The chaperone acts as a protective intermediary that shields GCase from rapid degradation and clearance, extending its circulation half-life and maintaining stable enzyme activity levels over extended periods. This eliminates the need for frequent infusions and simplifies the treatment regimen from multiple weekly injections to less frequent administrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The GCase chaperones significantly increase GCase activity and protein levels in brain cells, reducing substrate accumulation and associated pathology, offering a promising treatment for neuronopathic Gaucher disease and likely benefiting Parkinson's disease by improving protein folding and trafficking.
Implementation Method 1
The chaperone stabilizes GCase allowing prolonged drug efficacy
Implementation Method 2
enhancing lysosomal localization
Data Source
AI summary
Disclosed herein are β-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.